Product Description
Gefitinib is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It blocks the EGFR signaling pathway, inhibits tumor cell proliferation, angiogenesis, invasion and metastasis, and induces cancer cell apoptosis. It is a first-generation targeted drug for EGFR mutation-positive lung cancer, with precise targeting, good oral absorption and milder adverse reactions compared with chemotherapy.
Indications
First-line and subsequent treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with confirmed EGFR sensitive gene mutations.
Directions for Use
Oral administration, swallow whole with water. Recommended dose: 250 mg once daily, taken with or without food. Can be taken at any fixed time of the day. Do not crush, chew or split the tablet. Follow strict oncologist supervision during the whole course.
Product Features
- Standard 250mg clinical routine dose
- First-generation EGFR targeted therapy
- Oral convenient administration, no infusion needed
- Improves progression-free survival and quality of life
- Well-tolerated with controllable side effects
Storage
Store sealed in a cool dry place, protect from light, moisture and high temperature.
Warnings
- Contraindicated in patients with hypersensitivity to gefitinib or any excipients.
- Possible risk of interstitial lung disease; monitor cough, dyspnea closely.
- Common side effects: rash, diarrhea, dry skin, acne.
- Regularly monitor liver function during treatment.
- Avoid strong CYP3A4 inducers or inhibitors without medical advice.
- Not recommended for pregnant, lactating women and children.
- Keep out of reach of children.
